Ectica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on Targeting Stromal Cells in Cancer and Inflammatory Diseases.
Organised by the Cambridge Healthtech Institute (CHI), the virtual event will take place on April 22-23 2021.
The CHI Conference Program
The two day CHI Conference will feature leading scientists, researchers and industry professionals presenting on the main topics of: “Stromal-Immune Cell Interaction in Lymphoid Tissues: Guidance and Control”, “Stromal Cell-Driven Tissue Immunity: Origin and Identity”, “Stromal Cells in the Tumor Microenvironment: Function and Topology”, “Stromal Cells in the Tumor Microenvironment: Targets and Treatments”, “Stromal Cells in Chronic Inflammatory Diseases: Repair and Regeneration” and “Stromal Cells in Chronic Inflammatory Diseases: Transfer and Translation”.
Ectica Technologies presenting as a corporate sponsor at the CHI Conference on Targeting Stromal Cells in Cancer
At 10:00am EDT on Wednesday 21st April, Benjamin Simona, CEO of Ectica Technologies, will present on “Establishing Advanced ex-vivo Stromal Models using the 3DProSeed™ Hydrogel Platform”.
The innovative 3DProSeed hydrogel plate is the perfect tool to study tumor-stroma interactions in vitro. Ectica’s CEO will be presenting the technology and provide examples of the simple establishment of in vitro 3D stromal models using MSCs, RFCs, ECs and immune cells for subsequent co-culture with tumor cells. The synthetic nature of the hydrogels gives the highest control over the culture conditions and enables the study of endogenously secreted ECM and stromal factors.
About Stromal Cells
Stromal cells, also known as mesenchymal stem cells (MSCs), are key structural cells that construct tissue microenvironments, regulate tissue repair and provide critical growth and differentiation factors. Today, stromal cells are recognized as central regulators of immune responses in lymphoid organs and in inflamed tissues.
Targeting of stromal cells
The targeting of stromal cells, therefore, holds great promise for improving human health. The field of stromal cell research has gained substantial traction towards clinical application through the dissection of fundamental processes underpinning stromal cell function and the description of stromal cell heterogeneity in patients. This meeting will highlight cutting-edge science and provide important insights into recent developments towards therapeutic stromal cell targeting in cancer and chronic inflammatory diseases.